Bedrijfsoverzicht
TransMedics Group, Inc. is a commercial-stage medical technology firm dedicated to transforming organ transplant therapy for patients suffering from end-stage organ failure within the United States and internationally. The company operates within the Healthcare sector, specifically focusing on the Medical Devices industry, which implies a high barrier to entry driven by regulatory requirements and specialized technological innovation. TransMedics has established a significant market presence with a market capitalization of $3.91 billion and reported annual revenue of $605.49 million over the trailing twelve months. With an employee base of 898 individuals, the company demonstrates substantial operational scale, indicating that it has moved beyond early-stage development into a mature commercial phase capable of supporting extensive research, development, and manufacturing operations. These valuation and revenue figures suggest that the market views the firm as a major player in the organ preservation space, possessing the financial resources to sustain long-term growth initiatives and navigate the complex landscape of medical device regulation.
Financiële gezondheid
TransMedics Group reported a revenue of $605.49 million, net income of $190.29 million, and EBITDA of $134.47 million for the trailing twelve months. The substantial difference between revenue and net income reveals a highly efficient cost structure where the company retains a significant portion of its top-line growth as bottom-line profit, although the gap also reflects necessary expenditures in research and development and operational scaling. The company generated free cash flow of $94.00 million, which provides a robust buffer for financial flexibility, allowing management to fund capital expenditures, pursue strategic acquisitions, or reduce debt without relying on external financing. When analyzing profitability efficiency, the gross margin stands at 59.9%, indicating strong pricing power or low cost of goods sold relative to the high-value nature of organ perfusion technology. The operating margin of 13.2% highlights the significant overhead costs associated with scaling a medical device business, while the profit margin of 31.4% demonstrates exceptional net efficiency in converting revenue into actual earnings. On the balance sheet, the company holds $488.37 million in cash against $519.28 million in debt, resulting in a debt-to-equity ratio of 109.76, which characterizes the capital structure as moderately leveraged rather than conservative. Despite the leverage, the current ratio of 7.14 indicates an extremely strong short-term liquidity position, suggesting the firm can easily cover its current liabilities with its current assets. Furthermore, the return on equity of 54.2% and return on assets of 7.2% reveal that management is deploying capital with high effectiveness relative to shareholders' equity, though asset efficiency remains a standard benchmark for capital-intensive industries.
Waarderingsbeoordeling
The stock carries a trailing P/E ratio of 23.41 and a forward P/E of 30.95. The divergence between these two metrics implies that the market expects earnings to grow significantly in the future, as the forward multiple is higher than the trailing one, reflecting anticipated improvements in profitability. The price-to-book ratio is 8.26, which indicates that the market is pricing the company at a significant premium over its net asset value, signaling confidence in the intangible value of its technology and future revenue streams. Alternative valuation metrics include a price-to-sales ratio of 6.46 and an EV/EBITDA of 29.31, which suggest that investors are willing to pay a high multiple for every dollar of sales or earnings, typical for high-growth medical technology firms. Regarding trading range, the 52-week high is $156.00 and the 52-week low is $81.92. Without the specific current stock price provided in the facts, the precise percentage deviation from these levels cannot be calculated, but the wide range underscores the volatility inherent in the stock's recent performance. The beta value is 2.08, which means the stock is expected to be approximately twice as volatile as the broader market, indicating that price movements will likely amplify market swings with higher upside potential during rallies and deeper drawdowns during corrections.
Growth & Income
TransMedics Group has demonstrated aggressive expansion with a revenue growth rate of 32.2% year-over-year and an earnings growth rate of 1188.1% year-over-year. The earnings growth significantly outpaces the revenue growth, which implies a rapid improvement in operational leverage, margin expansion, or one-time income factors that have disproportionately boosted the bottom line compared to the top line. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all of its earnings to reinvest into growth initiatives such as product development and market expansion rather than distributing income to shareholders. This reinvestment strategy aligns with the growth profile of a commercial-stage medical technology company prioritizing capital allocation for future scalability over immediate income distribution. Overall, the company presents a growth-oriented financial profile characterized by double-digit revenue expansion, triple-digit earnings acceleration, and a capital allocation strategy focused entirely on internal reinvestment and market penetration.